{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:07Z","timestamp":1792012867805,"version":"4.4.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["311252\/Z\/24\/Z"],"award-info":[{"award-number":["311252\/Z\/24\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Juvenile idiopathic arthritis\u2013associated uveitis (JIA-U) is an important cause of childhood and adult visual impairment. Advances in surveillance approaches and treatment have improved outcomes, yet delayed detection and treatment-refractory disease remain substantial challenges. This review summarises recent developments across disease stratification, imaging, pharmacologic management, and psychosocial support, following the natural history of disease from inception to adulthood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Risk-stratified screening based on antinuclear antibody status, JIA subtype, and age at arthritis onset is now standard, but many cases present outside screening windows. Novel biomarkers, including S100A8\/A9, S100A12, and genetic risk alleles, offer promise for earlier identification. Ocular imaging modalities such as anterior segment optical coherence tomography and optical coherence tomography angiography enable objective, child-friendly detection of inflammation and subclinical vascular changes, potentially extending specialist-level assessment to community settings.<\/jats:p>\n                    <jats:p>Early initiation of immunomodulatory therapy in children with JIA is now prevalent care, reducing uveitis incidence and improving outcomes in childhood, although the consequence may be new challenges later in the lifecourse. Anti-tumour necrosis factor therapy has changed the management of JIA-U for the better, although precision strategies, such as anti-drug antibody monitoring, dose individualisation, and tapering approaches are needed to further optimise care. For refractory disease, biologics and other emerging therapies are under investigation, but new therapeutic targets are needed.<\/jats:p>\n                    <jats:p>Beyond ocular health, JIA-U imposes a heavy psychosocial burden on children and families, exacerbated by treatment side-effects and frequent medical visits. Validated tools, such as the EYE-Q questionnaire, and co-developed educational and self-management resources will be key to addressing mental health and quality-of-life concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>JIA-U remains a lifelong, vision-threatening condition despite advances in screening, diagnostics, and treatment. Integration of biomarker-based risk stratification, advanced imaging, and precision pharmacology holds promise for earlier detection and personalised care. Addressing psychosocial impacts through family-centred, multidisciplinary frameworks is essential. Future priorities include validating predictive biomarkers, refining tapering protocols, and ensuring equitable access to novel diagnostics and therapeutics to optimise lifelong outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-026-03758-1","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:19:40Z","timestamp":1772176780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel advances in juvenile idiopathic arthritis associated uveitis"],"prefix":"10.1186","volume":"28","author":[{"given":"Anamika","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha R.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-5864","authenticated-orcid":false,"given":"Ameenat Lola","family":"Solebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"1","key":"3758_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12969-025-01122-2","volume":"23","author":"X Peng","year":"2025","unstructured":"Peng X, Liu Q, Lin L, Dong L. The incidence and risk factors of uveitis in children with juvenile idiopathic arthritis (JIA): a meta -analysis and literature review. Pediatr Rheumatol. 2025;23(1):71.","journal-title":"Pediatr Rheumatol"},{"issue":"4","key":"3758_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jaapos.2019.04.008","volume":"23","author":"A Marino","year":"2019","unstructured":"Marino A, Weiss PF, Davidson SL, Lerman MA. Symptoms in noninfectious uveitis in a pediatric cohort: Initial presentation versus recurrences. J AAPOS. 2019;23(4):220. .","journal-title":"J AAPOS"},{"key":"3758_CR3","doi-asserted-by":"publisher","unstructured":"De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87(7):879-84. https:\/\/doi.org\/10.1136\/bjo.87.7.879.","DOI":"10.1136\/bjo.87.7.879"},{"key":"3758_CR4","doi-asserted-by":"crossref","unstructured":"Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol. 2003;135(5):676-80.","DOI":"10.1016\/S0002-9394(02)02148-7"},{"key":"3758_CR5","doi-asserted-by":"crossref","unstructured":"Solebo AL, Teoh L, Sargent J, Rahi JS. Avoidable childhood blindness in a high-income country: findings from the British childhood visual impairment and blindness study 2. Br J Ophthalmol. 2022;bjophthalmol-2022-321718.","DOI":"10.1136\/bjo-2022-321718"},{"issue":"9","key":"3758_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjo.80.9.844","volume":"80","author":"MS Suttorp-Schulten","year":"1996","unstructured":"Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"3758_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/09273948.2018.1441874","volume":"27","author":"NP Jones","year":"2019","unstructured":"Jones NP, Pradeep A, John B. Certification of vision impairment in patients with uveitis attending a specialist clinic. Ocul Immunol Inflamm. 2019;27(4):540\u20134.","journal-title":"Ocul Immunol Inflamm"},{"key":"3758_CR8","doi-asserted-by":"publisher","unstructured":"Haasnoot AMJW, Vernie LA, Rothova A, Doe PVD, Los LI, Schalij-Delfos NE et al. Impact of juvenile idiopathic arthritis associated uveitis in early adulthood. PLoS ONE. 2016;11(10)e0164312. https:\/\/doi.org\/10.1371\/journal.pone.0164312.","DOI":"10.1371\/journal.pone.0164312"},{"issue":"9","key":"3758_CR9","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/jcm11092471","volume":"11","author":"MP Paroli","year":"2022","unstructured":"Paroli MP, Abbouda A, Albanese G, Accorinti M, Falcione A, Spadea L, et al. Persistence of juvenile idiopathic Arthritis-Associated uveitis in adulthood: A retrospective study. J Clin Med. 2022;11(9):2471.","journal-title":"J Clin Med"},{"key":"3758_CR10","doi-asserted-by":"crossref","unstructured":"Angeles-Han ST, Srivastava SK. Screening, Monitoring, and Treating Children With Juvenile Idiopathic Arthritis-Associated Uveitis: Visualizing Better Outcomes. J Rheumatol. 2022;jrheum.221092.","DOI":"10.3899\/jrheum.221092"},{"issue":"6","key":"3758_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American college of Rheumatology\/Arthritis foundation guideline for the Screening, Monitoring, and treatment of juvenile idiopathic Arthritis\u2013Associated uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703\u201316.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3758_CR12","doi-asserted-by":"crossref","unstructured":"Foeldvari I, Bohn M, Petrushkin H, Angeles Han S, Bangsgaard R, Calzada-Hern\u00e1ndez J et al. A practical approach to uveitis screening in children with juvenile idiopathic arthritis. Br J Ophthalmol. 2025;109(3):372-6.\u00a0","DOI":"10.1136\/bjo-2023-324406"},{"issue":"4","key":"3758_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/rheumatology\/kep002","volume":"48","author":"H Foster","year":"2009","unstructured":"Foster H, Ramanan AV. The eyes have it! The need to improve awareness and access to early ophthalmological screening for juvenile idiopathic arthritis associated uveitis. Rheumatology. 2009;48(4):330\u20131.","journal-title":"Rheumatology"},{"issue":"8","key":"3758_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/bjo-2024-326674","volume":"109","author":"AL Solebo","year":"2025","unstructured":"Solebo AL, Kellett S, McLoone E, Petrushkin H, Gonzalez-Martin J, Ashworth J, et al. Incidence, sociodemographic and presenting clinical features of childhood non-infectious uveitis: findings from the UK National inception cohort study. Br J Ophthalmol. 2025;109(8):955\u201361.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3758_CR15","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to Anti-TNFs: Definition, Epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.","journal-title":"Clin Transl Gastroenterol"},{"key":"3758_CR16","doi-asserted-by":"crossref","unstructured":"I\u015f\u0131k S, Ar\u0131k SD, Akg\u00fcn \u00d6, Guliyeva V, Kavrul Kayaalp G, T\u00fcrkmen \u015e et al. How treatment choices influence the onset and outcomes of uveitis \u0131n juvenile idiopathic arthritis: a retrospective cohort study. Expert Opin Biol Ther. 2025;25(9):1025-33.","DOI":"10.1080\/14712598.2025.2545520"},{"issue":"5","key":"3758_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/acr.25482","volume":"77","author":"M Shishov","year":"2025","unstructured":"Shishov M, Weiss PF, Levy DM, Chang JC, Angeles-Han ST, Ogbu EA, et al. 25 years of biologics for the treatment of pediatric rheumatic disease: advances in prognosis and ongoing challenges. Arthritis Care Res (Hoboken). 2025;77(5):573\u201383.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"3758_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/1744666X.2020.1798230","volume":"16","author":"C Gaggiano","year":"2020","unstructured":"Gaggiano C, Sota J, Gentileschi S, Caggiano V, Grosso S, Tosi GM, et al. The current status of biological treatment for uveitis. Expert Rev Clin Immunol. 2020;16(8):787\u2013811.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"3758_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, Baptiste A, Despert V, Allain-Launay E, Kon\u00e9-Paut I, Belot A, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3758_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1745-6215-15-14","volume":"15","author":"AV Ramanan","year":"2014","unstructured":"Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15(1):14.","journal-title":"Trials"},{"key":"3758_CR21","doi-asserted-by":"crossref","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637-46.","DOI":"10.1056\/NEJMoa1614160"},{"key":"3758_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","volume":"268","author":"F Pichi","year":"2024","unstructured":"Pichi F, Smith SD, AlAli SH, Neri P. Adalimumab drug monitoring and treatment adjustment to drug antibodies in noninfectious uveitis. Am J Ophthalmol. 2024;268:306\u201311.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3758_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","volume":"39","author":"E Miserocchi","year":"2020","unstructured":"Miserocchi E, Giuffr\u00e8 C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847\u201351.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3758_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41584-024-01181-x","volume":"20","author":"SLN Clarke","year":"2024","unstructured":"Clarke SLN, Maghsoudlou P, Guly CM, Dick AD, Ramanan AV. The management of adult and paediatric uveitis for rheumatologists. Nat Rev Rheumatol. 2024;20(12):795\u2013808.","journal-title":"Nat Rev Rheumatol"},{"key":"3758_CR25","doi-asserted-by":"crossref","unstructured":"Parker DM, Angeles-Han ST, Stanton AL, Holland GN. Chronic anterior uveitis in children: psychosocial challenges for patients and their families. Am J Ophthalmol. 2018;191:xvi-xxiv.","DOI":"10.1016\/j.ajo.2018.03.028"},{"issue":"2","key":"3758_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10792-022-02462-8","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu S, Luo X, Huang C, Cao Q. Causal association of juvenile idiopathic arthritis-associated uveitis with depression and anxiety: a bidirectional Mendelian randomization study. Int Ophthalmol. 2022;43(2):589\u201396.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"3758_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13075-020-02166-3","volume":"22","author":"A Heiligenhaus","year":"2020","unstructured":"Heiligenhaus A, Klotsche J, Niewerth M, Horneff G, Ganser G, Haas JP, et al. Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. Arthritis Res Ther. 2020;22(1):81.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3758_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-020-0398-2","volume":"18","author":"N Aljaberi","year":"2020","unstructured":"Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, et al. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatr Rheumatol. 2020;18(1):7.","journal-title":"Pediatr Rheumatol"},{"issue":"13","key":"3758_CR29","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1167\/iovs.15-17066","volume":"56","author":"K Walscheid","year":"2015","unstructured":"Walscheid K, Heiligenhaus A, Holzinger D, Roth J, Heinz C, Tappeiner C, et al. Elevated S100A8\/A9 and S100A12 serum levels reflect intraocular inflammation in juvenile idiopathic Arthritis-Associated uveitis: results from a pilot study. Invest Opthalmology Visual Sci. 2015;56(13):7653.","journal-title":"Invest Opthalmology Visual Sci"},{"issue":"10","key":"3758_CR30","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3899\/jrheum.081302","volume":"36","author":"MS SOYFOO","year":"2009","unstructured":"SOYFOO MS, ROTH J, VOGL T, POCHET R. Phagocyte-specific S100A8\/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol. 2009;36(10):2190\u20134.","journal-title":"J Rheumatol"},{"issue":"4","key":"3758_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3109\/03009742.2015.1107128","volume":"45","author":"H Nordal","year":"2016","unstructured":"Nordal H, Brun J, Hordvik M, Eidsheim M, Jonsson R, Halse AK. Calprotectin (S100A8\/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with Infliximab. Scand J Rheumatol. 2016;45(4):274\u201381.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"3758_CR32","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/rheumatology\/key406","volume":"58","author":"A Heiligenhaus","year":"2019","unstructured":"Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, et al. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the inception cohort of newly diagnosed patients with juvenile idiopathic arthritis (ICON-JIA) study. Rheumatology. 2019;58(6):975\u201386.","journal-title":"Rheumatology"},{"issue":"7\u20138","key":"3758_CR33","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1080\/09273948.2020.1758731","volume":"29","author":"ST Angeles-Han","year":"2021","unstructured":"Angeles-Han ST, Miraldi Utz V, Thornton S, Schulert G, Rodriguez-Smith J, Kauffman A, et al. S100 Proteins, Cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic Arthritis-associated uveitis. Ocul Immunol Inflamm. 2021;29(7\u20138):1616\u201320.","journal-title":"Ocul Immunol Inflamm"},{"key":"3758_CR34","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1136\/annrheumdis-2024-eular.5780","volume":"83","author":"I Maccora","year":"2024","unstructured":"Maccora I, Altaye M, Greis K, Kaufman A, Dosunmu E, Duell A, et al. AB1361\u2005Proteomic analysis of tear fluid and aqueous humor of children with and without uveitis. Ann Rheum Dis. 2024;83:2033.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3758_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/09273948.2024.2428846","volume":"33","author":"I Maccora","year":"2025","unstructured":"Maccora I, Altaye M, Greis KD, Brunner HI, Duell A, Haffey WD, et al. Candidate Tear-Based uveitis biomarkers in children with JIA based on arthritis activity and topical corticosteroid use. Ocul Immunol Inflamm. 2025;33(4):603\u201312.","journal-title":"Ocul Immunol Inflamm"},{"issue":"23","key":"3758_CR36","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.3390\/jcm11237034","volume":"11","author":"L Garc\u00eda-Onrubia","year":"2022","unstructured":"Garc\u00eda-Onrubia L, Mateos Olivares M, Garc\u00eda-V\u00e1zquez C, Enr\u00edquez-de-Salamanca A, Cocho L, Herreras Cantalapiedra JM. Tear and plasma levels of cytokines in patients with uveitis: search for active disease biomarkers. J Clin Med. 2022;11(23):7034.","journal-title":"J Clin Med"},{"issue":"12","key":"3758_CR37","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/art.42955","volume":"76","author":"M Tordoff","year":"2024","unstructured":"Tordoff M, Smith SL, Lawson-Tovey S, Dick AD, Beresford MW, Ramanan AV, et al. Integration of genetic and clinical risk factors for risk classification of uveitis in patients with juvenile idiopathic arthritis. Arthritis Rheumatol. 2024;76(12):1789\u201396.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"3758_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/tjem.tjem_182_23","volume":"23","author":"\u015eK \u00c7orbac\u0131o\u011flu","year":"2023","unstructured":"\u00c7orbac\u0131o\u011flu \u015eK, Aksel G. Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value. Turk J Emerg Med. 2023;23(4):195\u20138.","journal-title":"Turk J Emerg Med"},{"issue":"3","key":"3758_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/bjophthalmol-2018-313200","volume":"104","author":"J Deng","year":"2020","unstructured":"Deng J, Tan H, Hu J, Su G, Cao Q, Huang X, et al. Genetic aspects of idiopathic paediatric uveitis and juvenile idiopathic arthritis associated uveitis in Chinese Han. Br J Ophthalmol. 2020;104(3):443\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3758_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/03009742.2016.1238959","volume":"46","author":"M Alberdi-Saugstrup","year":"2017","unstructured":"Alberdi-Saugstrup M, Enevold C, Zak M, Nielsen S, Nordal E, Berntson L, et al. Non-HLA gene polymorphisms in juvenile idiopathic arthritis: associations with disease outcome. Scand J Rheumatol. 2017;46(5):369\u201376.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"3758_CR41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jbspin.2016.04.014","volume":"84","author":"YM Pers","year":"2017","unstructured":"Pers YM, Le Blay P, Ludwig C, Rittore C, Tejedor G, Foliwe R, et al. Association of TRAF1-C5 with risk of uveitis in juvenile idiopathic arthritis. Joint Bone Spine. 2017;84(3):305\u20138.","journal-title":"Joint Bone Spine"},{"issue":"6","key":"3758_CR42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1080\/09273948.2019.1640883","volume":"28","author":"X Liu","year":"2020","unstructured":"Liu X, Solebo AL, Faes L, Beese S, Braithwaite T, Round ME, et al. Instrument-based tests for measuring anterior chamber cells in uveitis: A systematic review. Ocul Immunol Inflamm. 2020;28(6):898\u2013907.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"3758_CR43","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ajo.2008.06.004","volume":"146","author":"JH Kempen","year":"2008","unstructured":"Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol. 2008;146(6):813\u2013e8181.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3758_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jamaophthalmol.2022.6011","volume":"141","author":"JT Oatts","year":"2023","unstructured":"Oatts JT, Indaram M, de Alba Campomanes AG. Where have all the pediatric ophthalmologists Gone?\u2014Pediatric eye care scarcity and the challenge of creating equitable health care access. JAMA Ophthalmol. 2023;141(3):249.","journal-title":"JAMA Ophthalmol"},{"key":"3758_CR45","unstructured":"Royal College of Ophthalmologists. Facing workforce shortages and backlogs in the aftermath of COVID-19: the 2022 census of the ophthalmology consultant, trainee and SAS workforce. London ; 2023."},{"issue":"9","key":"3758_CR46","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41433-025-03755-9","volume":"39","author":"N Clough","year":"2025","unstructured":"Clough N, Magan T, Jain S. The UK paediatric ophthalmology workforce crisis \u2013 a National perspective. Eye. 2025;39(9):1793\u20136.","journal-title":"Eye"},{"issue":"2","key":"3758_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2023.09.018","volume":"131","author":"ST Berkowitz","year":"2024","unstructured":"Berkowitz ST, Finn AP, Parikh R, Kuriyan AE, Patel S. Ophthalmology workforce projections in the united States, 2020 to 2035. Ophthalmology. 2024;131(2):133\u20139.","journal-title":"Ophthalmology"},{"key":"3758_CR48","doi-asserted-by":"publisher","unstructured":"Gopal AD, Soares RR, Momenaei B, Wakabayashi T, Zhang Q, Martin J et al. Characteristics of uveitis specialists and disparities in geographic access to uveitis care in the united States. J Vitreoretin Dis. 2025;30:2474126425140473.\u00a0https:\/\/doi.org\/10.1177\/24741264251404733.","DOI":"10.1177\/24741264251404733"},{"key":"3758_CR49","doi-asserted-by":"crossref","unstructured":"del-Prado-S\u00e1nchez C, Llorca-Carde\u00f1osa A, Yeste-Mayoral B, Grixolli-Mazzon S, Barros-Centeno MF, D\u00edaz-Cascajosa J et al. Optical coherence tomography for the screening of anterior chamber inflammation in paediatric patients diagnosed with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2023.","DOI":"10.55563\/clinexprheumatol\/t7pn4v"},{"issue":"2","key":"3758_CR50","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/art.41530","volume":"73","author":"S Akbarali","year":"2021","unstructured":"Akbarali S, Rahi JS, Dick AD, Parkash K, Etherton K, Edelsten C, et al. Imaging-Based uveitis surveillance in juvenile idiopathic arthritis: Feasibility, Acceptability, and diagnostic performance. Arthritis Rheumatol. 2021;73(2):330\u20135.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"3758_CR51","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/bjophthalmol-2021-320448","volume":"107","author":"K Etherton","year":"2023","unstructured":"Etherton K, Rahi JS, Petrushkin H, Dick AD, Akbarali S, Pattani R, et al. Quantitative and qualitative assessment of anterior segment optical coherence tomography capture of disease state in childhood anterior uveitis. Br J Ophthalmol. 2023;107(7):966\u201372.","journal-title":"Br J Ophthalmol"},{"key":"3758_CR52","doi-asserted-by":"publisher","unstructured":"Diala FGI, McCarthy K, Chen JL, Tsui E. Multimodal imaging in pediatric uveitis. Ther Adv Ophthalmol. 2021;1325158414211059244. https:\/\/doi.org\/10.1177\/25158414211059244.","DOI":"10.1177\/25158414211059244"},{"key":"3758_CR53","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ajo.2022.05.012","volume":"241","author":"E Tsui","year":"2022","unstructured":"Tsui E, Chen JL, Jackson NJ, Leyva O, Rasheed H, Baghdasaryan E, et al. Quantification of anterior chamber cells in children with uveitis using anterior segment optical coherence tomography. Am J Ophthalmol. 2022;241:254\u201361.","journal-title":"Am J Ophthalmol"},{"key":"3758_CR54","doi-asserted-by":"crossref","unstructured":"Bellchambers A, Shu R, Chu CJ, Petrushkin H, Solebo AL. Differentiation of anterior chamber pigment and inflammatory cells using swept-source optical coherence tomography: a cross-sectional study. Eye (Lond). 2025.","DOI":"10.1038\/s41433-025-03697-2"},{"key":"3758_CR55","doi-asserted-by":"crossref","unstructured":"Ang T, Tong JY, Patel S, Selva D. Differentiation of bacterial orbital cellulitis and diffuse non-specific orbital inflammation on magnetic resonance imaging. Eur J Ophthalmol. 2024.","DOI":"10.1177\/11206721241272227"},{"issue":"3","key":"3758_CR56","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1167\/iovs.14-15118","volume":"56","author":"J Rose-Nussbaumer","year":"2015","unstructured":"Rose-Nussbaumer J, Li Y, Lin P, Suhler E, Asquith M, Rosenbaum JT, et al. Aqueous cell differentiation in anterior uveitis using Fourier-Domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2015;56(3):1430\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3758_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/iovs.65.1.9","volume":"65","author":"AL Solebo","year":"2024","unstructured":"Solebo AL, Bellchambers A, Kellett S, Rahi JS, Dick AD. Establishing the normative data set necessary for Imaging-Based childhood uveitis surveillance: A Cross-Sectional study. Invest Ophthalmol Vis Sci. 2024;65(1):9.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3758_CR58","doi-asserted-by":"publisher","first-page":"e0316410","DOI":"10.1371\/journal.pone.0316410","volume":"20","author":"S Dave","year":"2025","unstructured":"Dave S, Rahi JS, Petrushkin H, Testi I, Patel DE, Solebo AL. UVESCREEN1: A randomised feasibility study of imaging-based uveitis screening for children with juvenile idiopathic arthritis- study protocol. PLoS ONE. 2025;20(2):e0316410.","journal-title":"PLoS ONE"},{"key":"3758_CR59","doi-asserted-by":"crossref","unstructured":"Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Reviews. 2022;2022(10).","DOI":"10.1002\/14651858.CD013818.pub2"},{"issue":"8","key":"3758_CR60","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3899\/jrheum.171006","volume":"45","author":"V Cecchin","year":"2018","unstructured":"Cecchin V, Zannin ME, Ferrari D, Pontikaki I, Miserocchi E, Paroli MP, et al. Longterm safety and efficacy of adalimumab and Infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45(8):1167\u201372.","journal-title":"J Rheumatol"},{"issue":"5","key":"3758_CR61","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41433-023-02795-3","volume":"38","author":"EO Kreps","year":"2024","unstructured":"Kreps EO, Epps SJ, Consejo A, Dick AD, Guly CM, Ramanan AV. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye. 2024;38(5):871\u20136.","journal-title":"Eye"},{"key":"3758_CR62","doi-asserted-by":"crossref","unstructured":"Roberts JE, Nigrovic PA, Lo MS, Chang MH. Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children. JCR: Journal of Clinical Rheumatology. 2022;28(1):e301\u20134.","DOI":"10.1097\/RHU.0000000000001707"},{"key":"3758_CR63","doi-asserted-by":"crossref","unstructured":"Chen HC, Shunyakova J, Reddy AK, Pandiri S, Hassman L. Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis. Front Ophthalmol. 2025;5.","DOI":"10.3389\/fopht.2025.1432935"},{"issue":"10475","key":"3758_CR64","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(24)02468-1","volume":"405","author":"NR Acharya","year":"2025","unstructured":"Acharya NR, Ramanan AV, Coyne AB, Dudum KL, Rubio EM, Woods SM, et al. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet. 2025;405(10475):303\u201313.","journal-title":"Lancet"},{"issue":"5","key":"3758_CR65","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keac463","volume":"62","author":"L Kearsley-Fleet","year":"2023","unstructured":"Kearsley-Fleet L, Baildam E, Beresford MW, Douglas S, Foster HE, Southwood TR, et al. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis. Rheumatology. 2023;62(5):1926\u201335.","journal-title":"Rheumatology"},{"issue":"12","key":"3758_CR66","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Mesquida M, Ad\u00e1n A, Anton J, Ramanan AV, Carreno E, et al. Evidence for Tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183\u20138.","journal-title":"J Rheumatol"},{"issue":"3","key":"3758_CR67","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","volume":"2","author":"AV Ramanan","year":"2020","unstructured":"Ramanan AV, Dick AD, Guly C, McKay A, Jones AP, Hardwick B, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135\u201341.","journal-title":"Lancet Rheumatol"},{"key":"3758_CR68","doi-asserted-by":"publisher","unstructured":"Ramanan AV, Guly CM, Simonini G, Keller S, Sen P, Holzkaemper T et al. Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.25644.\u00a0Epub ahead of print.","DOI":"10.1002\/acr.25644"},{"issue":"5","key":"3758_CR69","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/FJC.0000000000001470","volume":"83","author":"JT Shah","year":"2024","unstructured":"Shah JT, Shah KT, Femia AN, Lo Sicco KI, Merola JF, Weber B, et al. Cardiovascular risk management in patients treated with Janus kinase inhibitors. J Cardiovasc Pharmacol. 2024;83(5):392\u2013402.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"3758_CR70","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40272-023-00594-7","volume":"25","author":"NK Bagri","year":"2023","unstructured":"Bagri NK, Chew C, Ramanan AV. Scope of JAK inhibitors in children: recent evidence and way forward. Pediatr Drugs. 2023;25(6):635\u201347.","journal-title":"Pediatr Drugs"},{"issue":"10315","key":"3758_CR71","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984\u201396.","journal-title":"Lancet"},{"issue":"11","key":"3758_CR72","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1167\/iovs.15-17351","volume":"56","author":"V Kalinina Ayuso","year":"2015","unstructured":"Kalinina Ayuso V, van Dijk MR, de Boer JH. Infiltration of plasma cells in the Iris of children with ANA-Positive anterior uveitis. Invest Opthalmology Visual Sci. 2015;56(11):6770.","journal-title":"Invest Opthalmology Visual Sci"},{"issue":"2","key":"3758_CR73","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaapos.2013.11.014","volume":"18","author":"ML Bratton","year":"2014","unstructured":"Bratton ML, He YG, Weakley DR. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J Am Association Pediatr Ophthalmol Strabismus. 2014;18(2):110\u20133.","journal-title":"J Am Association Pediatr Ophthalmol Strabismus"},{"issue":"1","key":"3758_CR74","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10792-016-0265-9","volume":"37","author":"F Pichi","year":"2017","unstructured":"Pichi F, Nucci P, Baynes K, Lowder CY, Srivastava SK. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol. 2017;37(1):221\u20138.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"3758_CR75","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40123-020-00328-9","volume":"10","author":"AS Ansari","year":"2021","unstructured":"Ansari AS, Amir Z, Williams GS. Bilateral 0.19\u00a0mg Fluocinolone acetonide intravitreal implant in the successful treatment of juvenile idiopathic Arthritis-Associated uveitis and secondary macular oedema: A case report and review of intravitreal therapies. Ophthalmol Ther. 2021;10(1):193\u2013200.","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"3758_CR76","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/aos.13744","volume":"96","author":"S Leinonen","year":"2018","unstructured":"Leinonen S, Immonen I, Kotaniemi K. Fluocinolone acetonide intravitreal implant (Retisert \u00ae) in the treatment of sight threatening macular oedema of juvenile idiopathic arthritis-related uveitis. Acta Ophthalmol. 2018;96(6):648\u201351.","journal-title":"Acta Ophthalmol"},{"key":"3758_CR77","doi-asserted-by":"publisher","unstructured":"Hasan N, Chawla R, Shaikh N, Kandasamy S, Azad SV, Sundar MD. A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology. Ther Adv Ophthalmol. 2022;14:25158414221097418.\u00a0https:\/\/doi.org\/10.1177\/25158414221097418.","DOI":"10.1177\/25158414221097418"},{"key":"3758_CR78","doi-asserted-by":"publisher","unstructured":"Xiao A, Feng Y, Yu S, Xu C, Chen J, Wang T et al. General anesthesia in children and long-term neurodevelopmental deficits: A systematic review. Front Mol Neurosci. 2022;15:972025. https:\/\/doi.org\/10.3389\/fnmol.2022.972025.","DOI":"10.3389\/fnmol.2022.972025"},{"key":"3758_CR79","doi-asserted-by":"publisher","unstructured":"Nordal E, Rypdal V, Christoffersen T, Aalto K, Berntson L, Fasth A et al. Incidence and predictors of uveitis in juvenile idiopathic arthritis in a nordic long-term cohort study. Pediatr Rheumatol. 2017;15(1):66. https:\/\/doi.org\/10.1186\/s12969-017-0195-8.","DOI":"10.1186\/s12969-017-0195-8"},{"key":"3758_CR80","doi-asserted-by":"crossref","unstructured":"Rypdal V, Glerup M, Songstad NT, Bertelsen G, Christoffersen T, Arnstad ED et al. Uveitis in juvenile idiopathic arthritis: 18-Year outcome in the Population-based nordic cohort study. Ophthalmology. 2021;128(4):598-608.","DOI":"10.1016\/j.ophtha.2020.08.024"},{"issue":"4","key":"3758_CR81","doi-asserted-by":"publisher","first-page":"e006071","DOI":"10.1136\/rmdopen-2025-006071","volume":"11","author":"L Scagnellato","year":"2025","unstructured":"Scagnellato L, Cozzi G, Lorenzin M, Poncina G, Rizzetto S, Ramonda R. Long-term outcomes of JIA-associated uveitis: a systematic review and meta-analysis. RMD Open. 2025;11(4):e006071.","journal-title":"RMD Open"},{"issue":"6","key":"3758_CR82","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/ard.2004.026955","volume":"64","author":"K Kotaniemi","year":"2005","unstructured":"Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, Leirisalo-Repo M. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis. 2005;64(6):871\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3758_CR83","doi-asserted-by":"publisher","first-page":"164","DOI":"10.31138\/mjr.32.2.164","volume":"32","author":"JR Ravan","year":"2021","unstructured":"Ravan JR, Chatterjee S, Singh P, Maikap D, Padhan P. Autoimmune rheumatic diseases masquerading as psychiatric disorders: A case series. Mediterr J Rheumatol. 2021;32(2):164.","journal-title":"Mediterr J Rheumatol"},{"issue":"1","key":"3758_CR84","doi-asserted-by":"publisher","first-page":"e301706","DOI":"10.1136\/bmjment-2025-301706","volume":"28","author":"A Mudra Rakshasa-Loots","year":"2025","unstructured":"Mudra Rakshasa-Loots A, Swiffen D, Steyn C, Marwick KFM, Smith DJ. Affective disorders and chronic inflammatory conditions: analysis of 1.5 million participants in our future health. BMJ Mental Health. 2025;28(1):e301706.","journal-title":"BMJ Mental Health"},{"issue":"3","key":"3758_CR85","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/acr.24491","volume":"74","author":"A Cassedy","year":"2022","unstructured":"Cassedy A, Altaye M, Andringa J, Cooper AM, Drews-Botsch C, Engelhard G, et al. Assessing the validity and reliability of the effects of youngsters\u2019 eyesight on quality of life questionnaire among children with uveitis. Arthritis Care Res (Hoboken). 2022;74(3):355\u201363.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3758_CR86","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41433-023-02659-w","volume":"38","author":"R Khalil","year":"2024","unstructured":"Khalil R, Kellett S, Petrushkin H, Twomey C, Rahi J, Solebo AL. Show don\u2019t tell: assessing the impact of co-developed patient information videos in paediatric uveitis. Eye. 2024;38(2):246\u201352.","journal-title":"Eye"},{"issue":"2","key":"3758_CR87","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.acap.2023.09.013","volume":"24","author":"C Twomey","year":"2024","unstructured":"Twomey C, McGonigle E, Solebo AL. Co-Creation of a novel childhood onset rare disease Self-Care support tool. Acad Pediatr. 2024;24(2):369\u201372.","journal-title":"Acad Pediatr"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03758-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03758-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03758-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:02:42Z","timestamp":1772182962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03758-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3758"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03758-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for use of the patient image within Fig.\u00a02 was gained as part of the Imaging in Childhood Uveitis study (National Health Service Health Research Authority REC approval reference 19\/SC\/0283).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Consultancy Fees, Alimera Sciences and Roche Ltd, Solebo Honorarium, Heidelberg Engineering, Solebo.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}